Key result
Adjunct diltiazem therapy in idiopathic dilated cardiomyopathy improved cardiac function and exercise capacity, with similar transplant listing-free survival compared to placebo (85% vs 80%; P=0.444).
Why the study?
Does adjunct diltiazem improve transplant listing-free survival, hemodynamics, and exercise capacity in patients with idiopathic dilated cardiomyopathy?
RCT (n=186)
double-blind
randomized
Yes
Does adjunct diltiazem improve transplant listing-free survival, hemodynamics, and exercise capacity in patients with idiopathic dilated cardiomyopathy?
Absolute Event Rate: 85% vs 80%
p-value: p=0.444
In patients with idiopathic dilated cardiomyopathy, adjunct diltiazem improved hemodynamics, exercise capacity, and subjective status without deleterious effects on transplant listing-free survival over 24 months.
No takes yet. Share an insight, caveat, or question.
Supports adjunct diltiazem for functional gains in idiopathic dilated cardiomyopathy without survival harm; extends calcium antagonist evidence in this population.
Figulla et al. (1996) conducted an RCT in Idiopathic Dilated Cardiomyopathy (n=186). diltiazem vs. placebo was evaluated on transplant listing-free survival (p=0.444). Adjunct diltiazem therapy in idiopathic dilated cardiomyopathy improved cardiac function and exercise capacity, with similar transplant listing-free survival compared to placebo (85% vs 80%; P=0.444).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: